At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 2, 2026 at 07:55 ET
UroGen Pharma refinanced its debt with Pharmakon Advisors, securing a $200 million initial tranche of a $250 million senior secured term loan at a fixed 8.25% interest rate, extending repayment to 2030. The move reduces the company's cost of capital and provides non-dilutive funding to support commercial operations and pipeline development, with no financial covenants attached.
- UroGen entered into an amended loan agreement with Pharmakon for a $250 million senior secured term loan in two tranches.
- First tranche of $200 million funded at closing to refinance existing $125 million debt and provide additional capital.
- Second tranche of $50 million available at UroGen’s discretion by June 30, 2027.
- Interest fixed at 8.25%, with repayment starting Q1 2030 in four equal quarterly installments.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access